Drugs and brands

Cagrilintide

Every GLP-1 the FDA has approved, and the active ingredient inside each one.

Definition

Novo Nordisk's long-acting amylin analog — a different receptor pathway from GLP-1 entirely, signaling satiety through the brainstem. Studied alone at 11.5% weight loss over 68 weeks in REDEFINE 1, and as the second half of CagriSema.

CagriSema REDEFINE trial results

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under Drugs and brands

Where the evidence lives